

Synthesis and Identification of New imidazolidine-4-one Derivatives and Study of their Biological Activity as Anti-bacteria, Fungi and oxidant.

Nagam Shihab Ahmed ^{1*}, Zeid Hassan Abood¹

¹Department of Chemistry - College of Science-University of Kerbala, Karbala, Iraq

* nagam.s@s.uokerbala.edu.iq

Received: 11 March (2026), Accepted:24 March 2026. Published: 31 March 2026

ABSTRACT

In this study, a new heterocyclic compound called imidazolidine-4-one derivatives was synthesized by first reacting thiosemicarbazide with carbon disulfide to create gate thiadiazole compound (A). This compound then interacted with 2-hydroxy benzoic acid to create azo compound (B), which then interacted with substituted phenyl amines to create Schiff base (S₁-S₈), which then reacted with 2-amino acetic acid to produce imidazolin-4-one derivatives. These compounds are characterized by ¹H MNR, ¹³C NMR, and Fourier-transform infrared spectroscopy (FT-IR). Next, we examine the biological characteristics of all heterocyclic derivatives to protect against two types of bacteria, one kind of fungus, and antioxidants. The novel-produced compounds'antioxidant activity was assessed using the DPPH. Compound G₄ (88%) have DPPH radical scavenging properties that are especially potent and equivalent to ascorbic acid. The synthesized compounds' antifungal efficacy using the diffusion method. Imidazolin-4-one derivatives were found to be more effective against Candida in an antifungal. The reducing abilities of the investigated compounds were measured. In antibacterial and anti fungi used less concentration that occur inhibition 2.5 mg/mL and high concentration used 20 mg/mL. This study provides key molecular insights that can be utilized to assess the antibacterial and antifungal activities of the Imidazolin-4-one ring and enhance its antioxidant properties.

Keywords: Azo, Imidazolidine-4-one derivatives, Schiff bases, Anti-oxidant, Anti-fungal, antibacterial

INTRODUCTION

Schiff base has been recognized as a crucial core component in medication creation over time. The preparation of Schiff base, named for Hugo Schiff [1], involved a condensation reaction between an aldehydic/ketonic carbonyl and amino functionality [2]. Schiff bases have been shown to have a wide range of pharmacological properties, including antimicrobial [3], anticancer [4], antitumor [5], anti-convulsant [6], antimalarial [7], antitubercular [8], anti-HIV, anti-inflammatory [9], and antidepressant activities, among others [10]. Their improved lipophilic nature, which increases their bioavailability in lipid membranes and causes growth redundancy in the organism, may be the cause of their increased reported bioactivity [11]. Amino acids [12], 1,2,4-triazole [13], sulfonamides [14], coumarins [15] or resacetophenone, aminothiazolylbromo coumarins, crown ethers [16], and O-Phthaldehyde [17] are other crucial areas of application of this framework that create favorable conditions for utilizing Schiff bases with antimicrobial potential. Tetrahydroimidazoles, commonly referred to as imidazolidines (saturated imidazoles), are biologically active heterocyclic compounds that contain nitrogen and have been shown to exhibit a wide range of noteworthy bioactivities [18]. Since they were discovered more than a century ago, imidazolidine-2,4-diones, often known as hydantoins, have gained widespread recognition. Imidazolidine derivatives, also known as hydantoins, are synthetic compounds with a variety of therapeutic uses. Imidazolidines and their derivatives have demonstrated anticonvulsive and antiarrhythmic pharmacological activities [19]. Hydantoins have found therapeutic applications in drugs like the well-known phenytoin [20]. The derivatives of imidazolidine have a significant role in medicinal chemistry due to their wide application as drugs and drug-intermediates [21]. Numerous imidazolidine derivatives have psychopharmacological qualities, such as phenytoin, which is well-known for its effectiveness as an anticonvulsant but is also useful in treating neuropathic pain [22]. Imidazolidine derivatives are present in numerous areas of medicinal chemistry, including antagonists of serotonin and fibrinogen receptors, inhibitors of the NMDA receptor's glycine binding site, antagonists of leukocyte cell adhesion, and allosteric inhibitors of protein–protein interactions [23]. Imidazolidine has two structural isomers: (1,2) and (1,3), Figure 1.




Figure 1. Imidazolidine isomers structural

This title was chosen depending on type of hetrocyclic synthesized compounds and activity tested to this compounds. In this research we used new substituted groups do not used in previous studies that give high activity in synthesized compounds. The aim of this study is to prepare new thiadiazole derivaties and to investigate their biological activity as antioxidants, antibacterial agents, and antifungals.

2. Materials and Procedures

1.2 Purchasing and getting ready

Sigma-Aldrich, Fluka, GCC, BDH, S.D. Fine, Scharlau, and Merck purchased synthetic starting ingredients, reagents, and solvents. A single spot-on silica TLC plate with an aluminum background (0.2 mm, 60 F254) was utilized to record the data for each pure component.

2.2 Methods of preparation

2.2.1 Synthesis Amino-1,3,4-thiadiazole-5-thiol [A] [24,25]

10 mL of carbon disulfide was added after 5.3 g, 50 mmol of anhydrous sodium carbonate, and 9.1 g, 100 mmol of thiosemicarbazide were agitated in 50 mL of pure ethyl alcohol for ten minutes. For a full day, the mixture was refluxed at roughly 70 degrees Celsius. After the reaction, a vacuum was used to remove the solvent. The solid was then dissolved in 100 milliliters of distilled water, filtered, and carefully acidified with strong hydrochloric acid to create a yellow solid that was filtered and dried. After that, distilled water was used to recrystallize the white crystalline product (10.64 g, 80%), mp 230–232 °C, Lit. 231 °C.

2.2.2.Synthesis of 2-Hydroxy-5-((5-mercapto-1,3,4-thiadiazol-2-yl)diazenyl)benzaldehyde (B) [26]

Compound (A) (3.99 g, 30 mmol) was dissolved in a solution of 25 mL of distilled water and 12 mL of HCl. Next, while stirring at 0°C, 2.07 g (30 mmol) of sodium nitrite was added gradually.


Next, 3.66 g (30 mmol) of salicylaldehyde was dissolved in 25 mL of 10% w/v NaOH at 0°C to create the phenoxide salt. The sodium phenoxide solution was carefully mixed with the diazonium chloride solution. The solution was allowed overnight to complete the precipitation process once addition was complete. Ethyl alcohol recrystallized the orange solid, yielding (2), yield (4.63g,58%), m.p. 189-191°C.

2.2.3. Synthesis of azoimines derivatives S₁-S₈ [27]

In an home microwave oven set to 300W for 15 minutes on a crucible, compound (B) (0.266 g, 1 mmol) and substituted phenyl amines (1 mmol) were combined with 1 mL of pure ethyl alcohol. Reactions have been completed using TLC (n-hexane: EtOAc, 1:2). Crude products were recrystallized using ethanol. Table (2-2) shows certain physical properties and other features for goods (S₁-S₈).


2.2.4. Synthesis of imidazolin-4-ones derivatives G₁-G₈ [28]

After stirring a mixture of Schiff bases (S₁-S₈) (0.0021 mol) in 9 mL of THF solvent, 2-aminoacetic acid (0.25 g, 0.0021 mol) in 5 mL of THF was refluxed for 16–20 hours. After cooling to room temperature, the liquid was filtered, cleaned, and recrystallized from acetone. Table 1 physical characteristics of compounds (G₁-G₈).



Scheme 1. Synthesis of derivatives of imidazolin-4-ones G₁-G₈ .

Scheme 2 illustrates the suggested chemical mechanism for ring closure that results in imidazolin-4-one in a THF solution.



Scheme 2.The creation of imidazolin-4-ones G_1 - G_8 in THF.

Table 1.Physical characteristics of every synthetic chemical substance.

Compound No.	Color	Rf <i>n</i> -hexane/EtOAc(1:2)	m.p. (°C)	Yield (%)
S₁	Dark brown	0.73	173-175	88
S₂	Orange	0.82	132-134	80
S₃	Dark red	0.62	154-156	76
S₄	Dark red	0.69	169-171	73
S₅	yellow	0.72	141-143	85
S₆	red	0.67	152-154	76
S₇	yellow	0.79	141-143	85
S₈	yellow	0.84	121-123	72
G₁	Dark brown	0.58	199-201	95
G₂	brown	0.69	212-214	89
G₃	Dark brown	0.51	163-165	81
G₄	light brown	0.55	174-176	90

G₅	Dark brown	0.53	150-152	88
G₆	light brown	0.56	168-170	90
G₇	Dark brown	0.59	155-157	86
G₈	light brown	0.61	178-180	91

2.3. Antibacterial activity

The antibacterial activity of the target 5-substituted Imidazolin-4-one compounds G1-G8 was assessed using *Staphylococcus aureus* (Gram-positive) and *Escherichia coli* (Gram-negative) bacteria using the agar diffusion technique [29]. Exact 1.25, 2.5, 5, 10, 15, and 20 mg of each investigated chemical were resolved in 1 milliliter of DMSO. Gentamycin, the reference antibiotic, was used as a control medication to compare the inhibitory zone results. Pure cultures of *Staphylococcus aureus* and *Escherichia coli*, were subcultured on appropriate media and incubated at 37 °C for 18–24 hours. Colonies were suspended in sterile saline and adjusted to 0.5 McFarland standard. Each investigated compound's inhibitory zone is displayed in Table 2

Table 2. Imidazolin-4-one derivatives G₁–G₈'s antibacterial activity

Compound No.	Concentration	Bacteria Type	
		<i>Staphylococcus Aureus</i> (G+)	<i>Escherichia Coli</i> (G-)
		Inhibitory zone (diameter) (mm)	
G ₁	1.25	NO	NO
G ₁	2.5	10.1	8.8
G ₁	5	12.5	11.7
G ₁	10	17	14.9
G ₁	15	18.9	20.3
G ₁	20	19.9	22.2
G ₂	1.25	NO	NO
G ₂	2.5	7.8	10
G ₂	5	9.1	10.6
G ₂	10	16.5	15.9
G ₂	15	19.2	19.5
G ₂	20	28.2	20.8

G ₃	1.25	NO	NO
G ₃	2.5	8.2	8.9
G ₃	5	8.9	9.4
G ₃	10	15.2	15.8
G ₃	15	19.7	19
G ₃	20	23.1	24.5
G ₄	1.25	NO	NO
G ₄	2.5	10	8.6
G ₄	5	10.6	9.7
G ₄	10	16.1	15
G ₄	15	18.8	19.3
G ₄	20	29.8	28.1
G ₅	1.25	NO	NO
G ₅	2.5	9.5	8.8
G ₅	5	10.2	9.3
G ₅	10	15.9	15
G ₅	15	19.5	19.6
G ₅	20	26.5	21.2
G ₆	1.25	NO	NO
G ₆	2.5	9.1	8.4
G ₆	5	9.8	9.8
G ₆	10	15.2	15
G ₆	15	18.9	19.4
G ₆	20	22.7	20.5
G ₇	1.25	NO	NO
G ₇	2.5	8.7	9.2
G ₇	5	9.5	10.4
G ₇	10	15.4	15.7
G ₇	15	19.7	19.2
G ₇	20	28.3	26.2
G ₈	1.25	NO	NO

G ₈	2.5	7.6	9.5
G ₈	5	8.4	9.9
G ₈	10	16.1	17.4
G ₈	15	19.7	20.5
G ₈	20	25.3	28.6
DMSO	-	-	-
Gentamycin	-	18	15




Figure 2. Inhibition zone of compounds G₁-G₈ on gram-negative and gram-positive bacteria

2.3. Antifungal activity

Candida fungus were used to assess the antifungal activity of the target 5-substituted Imidazolin-4-ones compounds G1-G8 using the agar diffusion technique [29]. Exact 1.25, 2.5, 5, 10, 15, and

20 mg of each investigated chemical were resolved in 1 mL of DMSO. The reference antibiotic, nystatin, was used as a control medication to compare the inhibitory zone results. Pure cultures of *Candida albicans* were subcultured on appropriate media and incubated at 37 °C for 48 hours. Colonies were suspended in sterile saline and adjusted to 0.5 McFarland standard. Each investigated compound's inhibitory zone is displayed in Table 3.

Table 3. Imidazolin-4-one derivatives G₁–G₈'s antifungal activity.

Compound No.	Concentration	Candida
		Inhibitory zone (diameter) (mm)
G ₁	1.25	NO
G ₁	2.5	6.9
G ₁	5	8.6
G ₁	10	16.8
G ₁	15	19.1
G ₁	20	22.0
G ₂	1.25	NO
G ₂	2.5	6.4
G ₂	5	9.6
G ₂	10	16.8
G ₂	15	18.9
G ₂	20	25.4
G ₃	1.25	NO
G ₃	2.5	6.6
G ₃	5	7.9
G ₃	10	16.1
G ₃	15	18.7
G ₃	20	22.2
G ₄	1.25	NO
G ₄	2.5	6.8
G ₄	5	7.7
G ₄	10	16.5

G ₄	15	18.2
G ₄	20	29.9
G ₅	1.25	NO
G ₅	2.5	6.6
G ₅	5	8.5
G ₅	10	16.3
G ₅	15	18.1
G ₅	20	24.8
G ₆	1.25	NO
G ₆	2.5	6.1
G ₆	5	8.3
G ₆	10	16.7
G ₆	15	18.5
G ₆	20	20.2
G ₇	1.25	NO
G ₇	2.5	6.4
G ₇	5	8.1
G ₇	10	16.4
G ₇	15	18.1
G ₇	20	28.2
G ₈	1.25	NO
G ₈	2.5	6.1
G ₈	5	7.5
G ₈	10	17.5
G ₈	15	18.5
G ₈	20	27.9
DMSO	-	-
Nystatin	-	21




Figure 3. Inhibition zone of compounds G₁-G₈ on candida

2.4. Determination of antioxidant activity

Using ascorbic acid as the standard solution, the DPPH assay was used to examine how well the produced compounds G₁–G₈ scavenged free radicals in vitro. Four milligrams of DPPH were dissolved in one hundred milliliters of ethanol to create a standard DPPH solution. Then, 200 μ L of each of the tested substances at varying concentrations were combined with 1000 μ L of the DPPH solution. The absorbance was measured at a wavelength of 517 nm using ethanol as a blank after the mixtures were incubated for 30 minutes at room temperature in the dark. The reference standard was ascorbic acid [30]. The following formula was used to get the percentage of DPPH free radical (% Inhibition):

$$\% \text{Inhibition} = \left[\frac{A^{\circ} - A_1}{A^{\circ}} \right] \times 100 \quad \dots (1)$$

Where: A[°] is the DPPH solution's absorbance in the absence of the sample

A₁ is the absorbance of the tested substance

3. Findings and conversation

3.1 Chemistry

Imidazolin-4-one derivatives G₁–G₈ were synthesized utilizing an effective approach that utilized reflux conditions (Scheme 1). The product is produced rapidly and with a high yield by this technically straightforward reaction. The hydrogens at positions 1 and 3 in the ¹H NMR spectra are the signals that demonstrate the creation of the imidazolin-4-one ring (Figure 4)




Figure 4. The synthetic imidazolin-4-one ring's general skeleton.

The hydrogen 3, a member of the asymmetric carbon 3, is another distinctive signal that manifests as singlet signals between 3.5 and 4 ppm. Carbons 1, 3, and 4 are the characteristic peaks in the ¹³C NMR spectra of imidazolin-4-one. At roughly 165–175 ppm, the carbonyl carbon 4 is the most deshielded signal in the spectrum. Methylene carbon 1 displays a sign in the range of 65–75 ppm, while carbon 3 shows at 46–52 ppm. (S₁–S₈) do not identification in ¹H NMR and ¹³C NMR because the are previous preparation in previous studies. Detailed illustrations of other signals are provided:

2-(2-hydroxy-5-((5-mercapto-1,3,4-thiadiazol-2-yl)diazenyl)phenyl)-3-(p-tolyl)imidazolidin-4-one (G₁, C₁₈H₁₆N₆O₂S₂). ¹H NMR (500 MHz, DMSO-*d*₆) δ (ppm, *J*H-H = Hz): 13.5-14.5(s,1H, S-H), 10.5- 11.5 (s,1H, Ar-OH), 8.5-9.5 (s,1H,-NH Imidazolidinone), 8.0-8.2(d ,1H , Ar-H) , 7.7-7.9(dd,1H,Ar-H), 7.3-7.5(d,2H,P-tolyl Ar-H), 7.1-7.2(m,3H, Ar-H (Tolyl and Phenol Overlapping)), 5.8-6.2(s,1H,-CH-Imidazolidinone Methine), 3.5- 4.0(s,2H, , -CH Imidazolidinone Methylene), 2.2-2.3(s,3H,CH₃methyl group).

¹³C NMR (125 MHz, DMSO-*d*₆) δ (ppm): 171.43 (C=O Imidazolidinone), 163.80(C-N=Nthiadiazole), 162.66(C-SH), 156.94(Ar-C-OH), 142.39(C-N=N),133.33(C-CH₃),115-130(Ar-C), 65 – 75 (N-CH-N imidazolidinone rin), 46.16(-CH imidazolidinone ring) and 20.09(-CH₃ methyl group) .

3-(2,4-dimethylphenyl)-2-(2-hydroxy-5-((5-mercapto-1,3,4-thiadiazol-2-yl)diazenyl)phenyl)imidazolidin-4-one(G₂,C₁₉H₁₈N₆O₂S₂) ¹H NMR (500 MHz, DMSO-*d*₆) δ (ppm, JH-H = Hz): 13.0-14.50(s,1H , S-H) ,10.5- 11.5 (s,,1H, Ar-OH),9.0-10.5 (s,1H,-NH Imidazolidinone),6.70-8.20(m ,6H , Ar-H),5.80-6.50(s,1H, -CH-Imidazolidinone Methine), 3.60-4.0(s,5H, Ar-H,-CH Imidazolidinone Methylene),2.20-2.40(s,3H,CH₃methyl group).

¹³C NMR (125 MHz, DMSO-*d*₆) δ (ppm): 173.25(C-SH), 168.18 (C=O Imidazolidinone), 163.09(C=Nthiadiazole), 155.44(Ar-C-OH), 151.08(C-O-CH₃) , 119.48(Ar-C),110-130(Ar-C), 65.85 (N-CH-N imidazolidinone ring), 49.10 (-CH imidazolidinone ring) and 20.59(-CH₃ Methyl substituent).

2-(2-hydroxy-5-((5-mercapto-1,3,4-thiadiazol-2-yl)diazenyl)phenyl)-3-(3-hydroxyphenyl)imidazolidin-4-one (G₃, C₁₇H₁₄N₆O₃S₂).¹H NMR (500 MHz, DMSO-*d*₆) δ (ppm, JH-H = Hz): 13.5-14.2 (s,1H, S-H),10.2- 11.0 (s,,1H, Ar-OH), 9.2-9.8(s,1H,Ar-H),8.5-9.2(s,1H,-NH Imidazolidinone), 8.0-8.3(d ,J=2,1H,Ar-H) ,7.8-8.0 (d , 1 H , Ar-H) ,7.0-7.2 (d , J=2,1H , Ar-H) , 6.5-7.4(m ,5H , Ar - H) , 5.8-6.5 (s,1H,-CH-Imidazolidinone Methine),3.6- 4.0(s,2H, -,CH Imidazolidinone Methylene).

¹³C NMR (125 MHz, DMSO-*d*₆) δ (ppm): 167.80(C=S thiadiazole), 165-175 (C=O Imidazolidinone), 162.11(C-N=N thiadiazole), 158.36(Ar-C-OH),139.83(C-N),126.75(Ar-C), 114.76(Ar-C),70.05 (N-CH-N imidazolidinone ring) and 47.56 (-CH imidazolidinone ring) .

2-(2-hydroxy-5-((5-mercapto-1,3,4-thiadiazol-2-yl)diazenyl)phenyl)-3-(2-hydroxyphenyl)imidazolidin-4-one (G₄, C₁₇H₁₄N₆O₃S₂).¹H NMR (500 MHz, DMSO-*d*₆) δ (ppm, JH-H = Hz): 13.5-14.2(s,1H,S-H),10.5-11.5 (s,,1H, Ar-OH)9.0-10.5(s,1H,Ar-OH),7.8-8.2 (d ,2H , Ar-H), ,6.7-7.6 (m ,5H ,Ar-OH)5.8 - 6.4(d,1H , -CH Imidazolidinone Methine),4.5 - 5.5(s,1H, -NH- Imidazolidinone Amine),3.5-4.2(m,2H,-CH Imidazolidinone Methylene).

¹³C NMR (125 MHz, DMSO-d₆) δ (ppm): 173.35 (C=O Imidazolidinone), 162.34(C-SH),160.89(Ar-C-OH), 152.58(C-N=Nthiadiazole), 134.73(C-N imidazolidinone ring),115-130(Ar-H), 66.81 (N-CH-N imidazolidinone ring), and 46.30 (-CH imidazolidinone ring).

2-(2-hydroxy-5-((5-mercapto-1,3,4-thiadiazol-2-yl)diazenyl)phenyl)-3-(3-

nitrophenyl)imidazolidin-4-one (G₅, C₁₇H₁₃N₇O₄S₂).¹H NMR (500 MHz, DMSO-d₆) δ (ppm, JH-H = Hz):13.5-14.5(s,1H , S-H) ,10.5- 11.5 (s,,1H, Ar-OH),8.5-10.5(s,1H,-NH Imidazolidinone), 8.5-8.7(s ,1H,Ar-H),8.0-8.2 (m ,, 1 H , Ar-H),7.6-7.9 (m ,2H , Ar-H), 7.8-8.1(s ,1H , Ar - H) , 6.9 - 7.5 (dd , J=8,2 , 2H , Ar-H),6.2-6.6 (s,1H,-CH-Imidazolidinone Methine),3.6- 4.0(s,2H , -CH Imidazolidinone Methylene).

¹³C NMR (125 MHz, DMSO-d₆) δ (ppm): 171.07 (C=O Imidazolidinone), 163.33(C-SH), 159.14(C-N=N thiadiazole), 157.98(Ar-C-OH), 150.00(C-NO₂),143.82(C-N=N),140-145(C-N), 110-135(Ar-C),70.79 (S-CH-N imidazolidinone ring) and 52.27 (-CH imidazolidinone ring) .

2-(2-hydroxy-5-((5-mercapto-1,3,4-thiadiazol-2-yl)diazenyl)phenyl)-3-(2-

methoxyphenyl)imidazolidin-4-one (G₆, C₁₈H₁₆N₆O₃S₂).¹H NMR (500 MHz, DMSO-d₆) δ (ppm, JH-H = Hz): 13.5-14.2 (s,1H , S-H) ,10.0- 10.8 (s,,1H, Ar-OH), 7.8 - 8.2 (d , 2H , Ar-H) , 6.8-7.6 (m,6H,Ar-H), 6.0-6.3 (s,1H,-CH-Imidazolidinone Methine), 4.2-5.0(s,1H,-NH Imidazolidinone), 3.75(s ,3H,OCH₃), 3.5- 3.8(s,2H , -CH Imidazolidinone Methylene).

¹³C NMR (125 MHz, DMSO-d₆) δ (ppm): 169.68 (C=O Imidazolidinone), 162.52(C=N thiadiazole),157.99(Ar-C-OH),153.62(C-O-CH₃),127.10(C-N),112-135(Ar-C),66.41 (N-CH-N imidazolidinone ring), 55.51(O-CH₃)and 49.94 (-CH imidazolidinone ring) .

2-(2-hydroxy-5-((5-mercapto-1,3,4-thiadiazol-2-yl)diazenyl)phenyl)-3-(4-

nitrophenyl)imidazolidin-4-one (G₇, C₁₇H₁₃N₇O₄S₂).¹H NMR (500 MHz, DMSO-d₆) δ (ppm, JH-H = Hz): 13.5-14.5(s,1H , S-H) ,10.5- 11.5 (s,,1H, Ar-OH),8.2-8.3(d , J=9 ,2H,Ar-H) ,7.8-8.0 (d , J=9, 2 H,Ar-H),7.6-7.9 (d , 1H, Ar-H), 7.1-7.4(m ,1H,Ar-H),6.8-7.1(d,1H,Ar-H),6.0-6.5 (s,1H,-CH-Imidazolidinone Methine), 4.5-5.5(s,1H,-NH Imidazolidinone),3.5- 4.0(s, 2H , -CH Imidazolidinone Methylene).

¹³C NMR (125 MHz, DMSO-*d*₆) δ (ppm): 171.69(C=S), 169.24 (C=O Imidazolidinone), 162.36(C=N thiadiazole), 156.90(Ar-C-OH), 148.80(C-N),141.40(C-NO₂),126-135(Ar-C), 115-135(Ar-C), 66.09(N-CH-N imidazolidinone ring) and 46.85 (-CH imidazolidinone ring) .

3-(4-chlorophenyl)-2-(2-hydroxy-5-((5-mercapto-1,3,4-thiadiazol-2-yl)diazenyl)phenyl)imidazolidin-4-one(G₈, C₁₇H₁₃ClN₆O₂S₂). ¹H NMR (500 MHz, DMSO-*d*₆) δ (ppm, JH-H = Hz): 13.5-14.2(s,1H,S-H),10.5- 11.5 (s,,1H, Ar-OH)9.0-10.5(s,1H,Ar-OH),7.8-8.2 (d ,2H , Ar-H) ,6.7-7.6 (m ,5H ,Ar-OH)5.8 - 6.4(d,1H , -CH Imidazolidinone Methine) ,4.5 - 5.5(s,1H , -NH- Imidazolidinone Amine),3.5-4.2(m,2H,-CH Imidazolidinone Methylene).

¹³C NMR (125 MHz, DMSO-*d*₆) δ (ppm): 169.99 (C=O Imidazolidinone), 163.12(C-N=Nthiadiazole), 159.80(C-SH), 155.10(Ar-C-OH), 146.72(C-N=N azo),128.28(C-Cl), 66.75 (N-CH-N imidazolidinone ring), and 51.53 (-CH imidazolidinone ring).

Tables 4 and 5 display the FT-IR spectrum and analytical data for the synthesized compounds A,B, S₁-S₈, and G₁-G₈.

Table 4. Compounds A, B, and S1-S8's FT-IR spectrum data (cm⁻¹)

Compound no.	A	B	S ₁	S ₂	S ₃	S ₄	S ₅	S ₆	S ₇	S ₈
v(O-H)	-	3421.83	3414.12	3450	3400-2500	3194	3446-3358	3441.12	3458.48	3414.12
v(C-H) aromatic	-	3060	3100	3050	3090	3194	3010	3161.43	3184.58	3167.22
v(C=O)	-	1637.62	-	-	-	-	-	-	-	-
v(C=N) imine	-	-	1618.33	1535	1616.47	1599.04	1627.97	1535.39	1614.47	1612.54
v(C=N) thiadiazole	1597	1618.33	1618.33	1535	1616.47	1599.04	1627.97	1535.39	1535.39	1612.54
v(C=C) aromatic	-	1550.82	1539.25	1504.53	1535	1492,1448	1595.18	1504.53-1398.44	1535.39-1500.47	1539.25-1491.
v(N=N)		1489.10	1402.30	1504.53	1535	1566.25	1595.18	1504.53	1500.47	1454.38

δ o.o.p (C-H) aromatic	-	831.35	812.02	812.06	835.21	837.13	842.92	812.06	750.33	856.42
Other bands (ν)	3399,3 281 (NH ₂)	1217(C-O)	2926 (C-H)aliphatic	2889 (C-H)aliphatic	1282 (C-O)	1290 (C-O)	1487,1329 (NO ₂)	1215.19 (C-O)	1460.16 - 1319.35 (NO ₂)	725.26 (C-Cl)

Table 5. Imidazolin-4-ones G1-G8 FT-IR spectrum data (°, cm⁻¹)

Compound No.	G₁	G₂	G₃	G₄	G₅	G₆	G₇	G₈
ν(O-H)	3400	3400-3100	3400-2400	3500-2500	3400-3100	3400	3414	3400-3100
ν(C-H) aliphatic	2953	2953	2964	2874	2989-2872	2953	2885	2968-2843
νC-H) aromatic	3160	3130	2964	2993	3074	3100	3074	3150
ν(C=O)	1690	1689	1691	1689	1691	1691	1700	1689
ν(C=N) thiadiazole	1599	1649	1645	1608	1643	1604	1597	1604
ν(C=C) benzene	1508	1512-1421	1475	1608	1600-1421	1604	1458-1425	1604
ν(N=N)	1599	1421	1475	1480	1643	1604	1597	1518
ν(S-H) thiol form	2500	2661	2656	2550	2656	2511	2549	2505
Other bands (ν)	1247(C-O)	1229(C-O)	1151(C-O)	1041(C-O)	1508-1309(NO ₂)	750(o.o.p.CH)	1527-1290(NO ₂)	898(o.o.p.CH)




Figure 11. ^1H NMR spectrum of compound G_7




Figure 12. ^1H NMR spectrum of compound G_8




Figure 13. ¹³C NMR spectrum of compound **G₁**




Figure 14. ¹³C NMR spectrum of compound **G₂**




Figure 17: ^{13}C NMR spectrum of compound G_5




Figure 18: ^{13}C NMR spectrum of compound G_6

3.2. Biological techniques

3.2.1. Activity against bacteria

The antibacterial activity of the generated compounds was assessed against *Escherichia coli*, a gram-negative bacterium, and *Staphylococcus aureus*, a gram-positive bacterium, using the diffusion method [28]. Imidazolin-4-one derivatives were found to be more effective than Gentamycin as a control medication against *Escherichia coli* and *Staphylococcus aureus* in an antibacterial investigation.

3.2.2 Activity against fungus

The synthesized compounds' antifungal efficacy against *Candida* fungus was assessed using the diffusion method [28]. Imidazolin-4-one derivatives were found to be more effective than nystatin as a control medication against *Candida* in an antifungal investigation.

3.2.3. The DPPH test

The generated compounds' antioxidant activity is investigated using the DPPH method. The reducing abilities of the investigated compounds were measured by their capacity to change the purple 1,1-diphenyl-2-picrylhydrazyl radical (DPP•) into its light-yellow reduced form (DPPH). A decrease in violet color was seen at 517 nm, and the absorbance reduction correlates with the substance's antioxidant activity. Utilizing ascorbic acid at concentrations of 50, 100, 150, 200, and 250 mg/mL as the control material, compare the outcomes. The findings show that all drugs performed exceptionally well at the 250 mg/mL concentration. Compounds G₃ (86%), G₄ (88%), and G₆ (85%) have exceptionally potent DPPH radical scavenging properties that are on par with ascorbic acid (85%). The H• of the investigated molecule is transferred to the N• of the DPPH radical reagent via SET and/or HAT kinds of antioxidant processes [31]. One possible location for H atom donation is the hydrogens at the C3 positions of the Imidazolidin-4-one ring, a five-membered heterocyclic ring. This ring's antioxidant activity must result from the straightforward transfer of a H atom to the radicals; the most widely used mechanism is hydrogen atom transfer (HAT). The Imidazolidin-4-one derivatives exhibit antioxidant effects primarily attributed to resonance effects and tautomeric equilibrium. The scavenging activities of synthesized compounds G1-G8 are presented in Table 6 and Graph 1.

4. Conclusion

This study provides key molecular insights that can be utilized to assess the antibacterial and antifungal activities of the Imidazolin-4-one ring and enhance its antioxidant properties.

Acknowledgment

We acknowledge the support received from the service laboratory at the Department of Chemistry, College of Science, University of Kerbala in completing this research.

Author contributions The manuscript was prepared with contributions from all authors. All authors have approved the final version of the manuscript.

Funding This project did not receive any funding

Data availability No datasets were generated or analyzed during the current study. Declarations

Ethical approval Not applicable

Competing interests The authors declare no competing interests

References

1. Raczuk, E., Dmochowska, B., Samaszko-Fiertek, J. and Madaj, J., 2022. Different Schiff bases structure, importance and classification. *Molecules*, 27(3), p. 787. doi.org/10.3390/molecules27030787.
2. Deb, B., Debnath, S., Chakraborty, A. and Majumdar, S., 2021. Bis-indolylation of aldehydes and ketones using silica-supported FeCl₃: molecular docking studies of bisindoles by targeting SARS-CoV-2 main protease binding sites. *RSC Advances*, 11(49), pp. 30827-30839. doi.org/10.1039/D1RA05336B.
3. Ceramella, J., Iacopetta, D., Catalano, A., Cirillo, F., Lappano, R. and Sinicropi, M.S., 2022. A review on the antimicrobial activity of Schiff bases: Data collection and recent studies. *Antibiotics*, 11(2), p. 191. doi.org/10.3390/antibiotics11020191 .
4. Tsacheva, I., Todorova, Z., Momekova, D., Momekov, G. and Koseva, N., 2023. Pharmacological activities of Schiff bases and their derivatives with low and high molecular phosphonates. *Pharmaceuticals*, 16(7), p. 938. doi.org/10.3390/ph16070938.

5. Iacopetta, D., Ceramella, J., Catalano, A., Saturnino, C., Bonomo, M.G., Franchini, C. and Sinicropi, M.S., 2021. Schiff bases: Interesting scaffolds with promising antitumoral properties. *Applied Sciences*, 11(4), p. 1877. doi.org/10.3390/app11041877 .
6. Sahu, R. and Shah, K., 2024. Schiff bases: a captivating scaffold with potential anticonvulsant activity. *Mini Reviews in Medicinal Chemistry*, 24(18), pp. 1632-1650. doi.org/10.2174/1389557523666230608151523.
7. Dahlawi, H.A. and Asif, M., 2025. Pharmacological Potential and Biological Applications of Various Schiff Base Analogues. *Russian Journal of Organic Chemistry*, 61(12), pp. 2367-2390. doi.org/10.1134/S107042802512012X.
8. Meeran, I.S., Raja, T.W., Dusthakeer, V.A., Ali, M.M.N., Tajudeen, S.S. and Shabeer, T.K., 2022. An insight into antimycobacterial and antioxidant potentials of INH-Schiff base complexes and in silico targeting of MtKasB receptor of *M. tuberculosis*. *New Journal of Chemistry*, 46(10), pp. 4620-4633. doi.org/10.1039/D1NJ05928J.
9. Mushtaq, I., Ahmad, M., Saleem, M. and Ahmed, A., 2024. Pharmaceutical significance of Schiff bases: an overview. *Future Journal of Pharmaceutical Sciences*, 10(1), p. 16. doi.org/10.1186/s43094-024-00585-w.
10. Biswas, T., Mittal, R.K., Sharma, V., Kanupriya and Mishra, I., 2024. Schiff bases: versatile mediators of medicinal and multifunctional advancements. *Letters in Organic Chemistry*, 21(6), pp. 505-519. doi.org/10.2174/1570178620666230816142416
11. Mendonça, J.D.S., Guimarães, R.D.C.A., Zorgetto-Pinheiro, V.A., Fernandes, C.D.P., Marcelino, G., Bogo, D., Frelander, A., de Oliveira, P.A. and Nascimento, V.A.D., 2022. Natural antioxidant evaluation: A review of detection methods. *Molecules*, 27(11), p. 3563. doi.org/10.3390/molecules27113563.
12. Biswas, T., Mittal, R.K., Sharma, V., Kanupriya and Mishra, I., 2024. Schiff bases: versatile mediators of medicinal and multifunctional advancements. *Letters in Organic Chemistry*, 21(6), pp. 505-519. doi.org/10.2174/1570178620666230816142416
13. Hozien, Z.A., El-Mahdy, A.F., Markeb, A.A., Ali, L.S. and El-Sherief, H.A., 2020. Synthesis of Schiff and Mannich bases of new s-triazole derivatives and their potential applications for removal of heavy metals from aqueous solution and as antimicrobial agents. *RSC Advances*, 10(34), pp. 20184-20194. doi.org/10.1039/D0RA03417H

14. Bishoyi, A.K., Mahapatra, M., Sahoo, C.R., Paidesetty, S.K. and Padhy, R.N., 2022. Design, molecular docking and antimicrobial assessment of newly synthesized p-cuminal-sulfonamide Schiff base derivatives. *Journal of Molecular Structure*, 1250, p. 131824. doi.org/10.1016/j.molstruc.2021.131824.
15. Abdel-Kader, N.S., Moustafa, H., El-Ansary, A.L., Sherif, O.E. and Farghaly, A.M., 2021. A coumarin Schiff base and its Ag(i) and Cu(ii) complexes: synthesis, characterization, DFT calculations and biological applications. *New Journal of Chemistry*, 45(17), pp. 7714-7730. doi.org/10.1039/D0NJ05891C
16. Mustafa, Y.F., 2025. Coumarins as bioorganic building blocks in drug design, biocatalysis, and sensing. *Russian Journal of Bioorganic Chemistry*, 51(6), pp. 2390-2416. doi.org/10.1134/S106816202512015X.
17. Nasser, A.T. and Al-Asadi, R., 2023. Schiff bases ligands derived from o-phthalaldehyde and their metal complexes with Cu²⁺ and Ni²⁺: Synthesis, anti-breast cancer and molecular docking study. *Trends in Sciences*, 20(9), p. 5675. doi.org/10.48048/tis.2023.5675.
18. Shalo, R.R., Karthiga, A.R., Divyabharathi, S., Rajeswari, K. and Vidhyasagar, T., 2025. Novel highly unsymmetrical Imidazolidines as potential anticancer agents: Design, synthesis, crystal structure, in silico & in vitro evaluation. *Journal of Molecular Structure*, p. 144804. doi.org/10.1016/j.molstruc.2025.144804.
19. Muhubhupathi, G., Selvakumar, M., Mohanapriya, K., Brindha, T., Brindha, B.S., Mahalakshmi, Y. and Gayathri, P., 2025. Imidazolidine derivatives: A comprehensive review of their biological activities and therapeutic potential. *Asian Journal of Research in Chemistry*, 18(1), pp. 41-51. doi.org/10.52711/0974-4150.2025.00006.
20. Shinde, N.V., Patole, V.P., Kumbhare, M.R., Narkhede, H., Satalkar, A.T., Thube, A.V. and Bhosale, S.K., 2026. Exploring hydantoin frameworks: synthetic approaches and therapeutic potential. *Future Journal of Pharmaceutical Sciences*, 12(1), p. 13. doi.org/10.1186/s43094-025-00721-y.
21. Faisca Phillips, A.M., Guedes da Silva, M.F.C. and Pombeiro, A.J., 2020. The stereoselective nitro-Mannich reaction in the synthesis of active pharmaceutical

- ingredients and other biologically active compounds. *Frontiers in Chemistry*, 8, p. 30. doi.org/10.3389/fchem.2020.00030.
22. Czopek, A., Byrtus, H., Góra, M., Rapacz, A., Sałat, K., Koczurkiewicz-Adamczyk, P., Pytka, K., Latacz, G. and Kamiński, K., 2025. Synthesis, anticonvulsant, antinociceptive activity and preliminary safety evaluations of novel hybrid imidazolidine-2,4-dione derivatives with morpholine moiety. *ChemMedChem*, 20(7), p. e202400612. doi.org/10.1002/cmdc.202400612.
23. Trišović, N. et al. (2011) 'Synthesis, characterization and antimicrobial activity of some new Schiff bases derived from 3-amino-5-methylisoxazole', *Journal of the Serbian Chemical Society*, 76(12), pp. 1597–1606. doi: 10.2298/JSC110304144T.
24. Akram, E., Daham, S. N., Rashad, A. A. and Mahmood, A. E. (2019) 'Synthesis and Evaluation the Activity of 1, 3, 4-Thiadiazole Derivatives as Antibacterial Agent Against Common Pathogenic Bacteria', *Al-Nahrain Journal of Science*, 22(1), pp. 25–32. doi: 10.21123/adbs.2019.22.1.0025.
25. Radwan, A. A., Alanazi, F. K. and Al-Agamy, M. H. (2011) 'Synthesis and evaluation of new 2-substituted benzimidazole derivatives as anti-Candida albicans', *Journal of Enzyme Inhibition and Medicinal Chemistry*, 26(1), pp. 1–12. doi: 10.3109/14756360903524316.
26. Tan, J., Zheng, T., Xu, K. and Liu, C. (2017) 'Aryne triggered [2,3]-sigmatropic rearrangement of allyl and propargyl thioethers', *Organic & Biomolecular Chemistry*, 15(23), pp. 4946–4950. doi: 10.1039/C7OB00994B.
27. Bekdemir, Y. and Efil, K. (2014) 'Microwave Assisted Solvent-Free Synthesis of Some Imine Derivatives', *Organic Chemistry International*, 2014, Art. no. 816487. doi: 10.1155/2014/816487.
28. Al-Adhami, H. and Al-Majidi, S. M. (2021) 'Synthesis, Characterization of Thiazolidin-4-one, Oxazolidin-4-one and Imidazolidin-4-one Derivatives from 6-Amino-1, 3-dimethyluracil and evaluation of their Antioxidant and Antimicrobial Agent', *Al-Qadisiyah Journal of Pure Science*, 26(4), pp. 59–72. doi: 10.29350/qjps.2021.26.4.1415.
29. Finn, R. (1959) 'Theory of agar diffusion methods for bioassay', *Analytical Chemistry*, 31(6), pp. 975–977. doi: 10.1021/ac60150a040.

30. Xiao, F., Xu, T., Lu, B. and Liu, R. (2020) 'Guidelines for antioxidant assays for food components', *Food Frontiers*, 1(1), pp. 60–69. doi: 10.1002/fft2.10.
31. Cuendet, M., Hostettmann, K., Potterat, O. and Dyatmiko, W. (1997) 'Iridoid glucosides with free radical scavenging properties from *Fagraea blumei*', *Helvetica Chimica Acta*, 80(4), pp. 1144–1152. doi: 10.1002/hlca.19970800411.